Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Real-World Experience of Pola-R-CHP Therapy in Diffuse Large B-Cell Lymphoma Aged 80 or Older

Nobuhiro Kanemura, Toshiki Yamada, Hideko Goto, Takeshi Hara, Senji Kasahara, Kenji Fukuno, Michio Sawada, Hiroshi Nakamura, Nobuhiko Nakamura, Shin Lee, Kei Fujita, Tomomi Suzaki, Naoki Hayase, Takayuki Goto, Masahito Shimizu, Hisashi Tsurumi

Blood (2024) 144 (Supplement 1): 3089.

https://doi.org/10.1182/blood-2024-200404

Published: 2024

Journal Articles

A Comparison of THP- Cop and CHOP for Peripheral T-Cell Lymphoma, Not Otherwise Specified

Yuhei Shibata, MD, Nobuhiko Nakamura, MD PhD, Senji Kasahara, MD PhD, Toshiki Yamada, MD PhD, Michio Sawada, MD PhD, Takeshi Yoshikawa, MD PhD, Hiroshi Nakamura, MD, Junichi Kitagawa, MD PhD, Nobuhiro Kanemura, MD PhD, Naoe Goto, MD PhD, Takeshi Hara, MD PhD, Koshiro Saito, MD PhD, Hisashi Tsurumi, MD PhD

Blood (2014) 124 (21): 3059.

https://doi.org/10.1182/blood.V124.21.3059.3059

Published: 2014

Journal Articles

A Randomized Phase II/III Study of R-THP-Cop Vs R-CHOP for Patients Younger Than 70 Years with DLBCL

Naoe Goto, MD PhD, Takuro Matsumoto, MD, Yuhei Shibata, MD, Junichi Kitagawa, MD PhD, Nobuhiro Kanemura, MD PhD, Yoshikawa Takeshi, MDPhD, Senji Kasahara, MD PhD, Hideko Goto, MDPhD, Kenji Fukuno, MD, Takeshi Hara, MD PhD, Toshiki Yamada, MD PhD, Michio Sawada, MD PhD, Takeshi Takahashi, MDPhD, Koshiro Saito, MD PhD, Hisataka Moriwaki, Prof., Hisashi Tsurumi, MD PhD

Blood (2014) 124 (21): 3078.

https://doi.org/10.1182/blood.V124.21.3078.3078

Published: 2014

Journal Articles

High Response Rate and Acceptable Toxicity of R-P-Imvp-16/CBDCA for Relapsed or Refractory Aggressive B-Cell Lymphoma

Takuro Matsumoto, MD, Nobuhiko Nakamura, MD PhD, Yuhei Shibata, MD, Hiroshi Nakamura, MD, Ryoko Mabuchi, MD, Junichi Kitagawa, MD PhD, Nobuhiro Kanemura, MD PhD, Naoe Goto, MD PhD, Senji Kasahara, MD PhD, Hideko Goto, MD PhD, Kenji Fukuno, MD PhD, Takeshi Hara, MD PhD, Toshiki Yamada, MD PhD, Michio Sawada, MD PhD, Takeshi Takahashi, MD PhD, Masami Oyama, MD PhD, Koshiro Saito, MD PhD, Hisashi Tsurumi, MD PhD

Blood (2014) 124 (21): 4418.

https://doi.org/10.1182/blood.V124.21.4418.4418

Published: 2014

Journal Articles

Serum Interleukin-18 Level Determines Clinical Outcome in Patients with Diffuse Large B-Cell Lymphoma in Rituximab Era.

Naoe Goto, Hisashi Tsurumi, MD, PhD, Senji Kasahara, Takeshi Hara, Nobuhiro Kanemura, Takeshi Yoshikawa, Soranobu Ninomiya, Kengo Ogawa, Toshiki Yamada, MD, Michio Sawada, Tsuyoshi Takami, Hisataka Moriwaki

Blood (2009) 114 (22): 1926.

https://doi.org/10.1182/blood.V114.22.1926.1926

Published: 2009

Journal Articles

A Phase II Study of the Combination Chemotherapy Consisted of Rituximab and THP-COP Regimen as First-Line Treatment for Patients with Diffuse Large B-Cell Lymphoma

Hisashi Tsurumi, MD, PhD, Naoe Goto, Takeshi Hara, Senji Kasahara, Nobuhiro Kanemura, Junichi Kitagawa, MD, Takeshi Yoshikawa, Toshiki Yamada, Michio Sawada, Takeshi Takahashi, Tsuyoshi Takami, Hisataka Moriwaki

Blood (2008) 112 (11): 3599.

https://doi.org/10.1182/blood.V112.11.3599.3599

Published: 2008

Journal Articles

Second Report of Clinical Significance of sFas for DLBCL Treated with CHOP and New Analysis of sFas for DLBCL Treated with R-CHOP.

Hisashi Tsurumi, Takeshi Hara, Jun-ichi Kitagawa, Naoe Goto, Nobuhiro Kanemura, Senji Kasahara, Toshiki Yamada, Hisataka Moriwaki

Blood (2007) 110 (11): 1570.

https://doi.org/10.1182/blood.V110.11.1570.1570

Published: 2007

Journal Articles

Serum-Soluble Interleukin-2 Receptor (sIL-2R) Is an Extremely Strong Prognostic Factor for Patients with Peripheral T-Cell Lymphoma, Unspecified (PTCL-U).

Takeshi Hara, Hishasi Tsurumi, Jun-ichi Kitagawa, Naoe Goto, Nobuhiro Kanemura, Senji Kasahara, Toshiki Yamada, Hisataka Moriwaki

Blood (2007) 110 (11): 3455.

https://doi.org/10.1182/blood.V110.11.3455.3455

Published: 2007

Journal Articles

The Combination of 9-cis Retinoic Acid Plus MEK Inhibitor Induces Apoptosis Via Dephosphorylation of Retinoid X Receptor α in HL-60R Cells.

Nobuhiro Kanemura, MD, Hisashi Tsurumi, MD, Senji Kasahara, MD, Takeshi Hara, MD, Toshiki Yamada, MD, Masahito Shimizu, MD, Hisataka Moriwaki, MD

Blood (2006) 108 (11): 1927.

https://doi.org/10.1182/blood.V108.11.1927.1927

Published: 2006

Journal Articles

Continuous Drip Infusion of Low Dose Cytrabine and Etoposide with Granulocyte Colony-Stimulating Factor for Elderly Acute Myeloid Leukemia Patients Hardly Tolerable Intensive Chemotherapy - Phase II Study.

Nobuhiro Kanemura, MD, Hisashi Tsurumi, MD, PhD, Takeshi Hara, MD, PhD, Senji Kasahara, MD, PhD, Naoe Goto, MD, Kenji Fukuno, MD, Toshiki Yamada, MD, PhD, Michio Sawada, MD, PhD, Hisataka Moriwaki, MD, PhD

Blood (2005) 106 (11): 1858.

https://doi.org/10.1182/blood.V106.11.1858.1858

Published: 2005

Journal Articles

Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies

Satoshi Takahashi, Tohru Iseki, Jun Ooi, Akira Tomonari, Kashiya Takasugi, Yoko Shimohakamada, Toshiki Yamada, Kaoru Uchimaru, Arinobu Tojo, Naoki Shirafuji, Hideki Kodo, Kenzaburo Tani, Tsuneo Takahashi, Takuhiro Yamaguchi, Shigetaka Asano

Blood (2004) 104 (12): 3813–3820.

https://doi.org/10.1182/blood-2004-03-1001

Published: 2004

Journal Articles

Serum Interleukin-18 Levels Are Associated with Response to Treatment and Survival in Patients with Aggressive Non-Hodgkin’s Lymphoma.

Naoe Goto, MD, Hisashi Tsurumi, MD, PhD, Masao Takemura, PhD, Takeshi Hara, MD, PhD, Michio Sawada, MD, PhD, Toshiki Yamada, MD, PhD, Senji Kasahara, MD, PhD, Nobuhiro Kanemura, MD, Takeshi Takahashi, MD, PhD, Mitsuru Seishima, MD, PhD, Tsuyoshi Takami, MD, PhD, Koshiro Saito, MD, PhD, Hisataka Moriwaki, MD, PhD

Blood (2004) 104 (11): 4543.

https://doi.org/10.1182/blood.V104.11.4543.4543

Published: 2004

Journal Articles

Fas or Fas Ligand Expression Can Determine the Clinical Outcome of Germinal Center Type in Diffuse Large B Cell Lymphoma.

Yasushi Kojima, MD, Hisashi Tsurumi, MD, PhD, Naoe Goto, MD, Michio Sawada, MD, PhD, Toshiki Yamada, MD, PhD, Takeshi Hara, MD, PhD, Takeshi Takahashi, MD, PhD, Tetsuya Yamada, MD, PhD, Masanao Saio, MD, PhD, Eiichi Tomita, MD, PhD, Tsuyoshi Takami, MD, PhD, Hisataka Moriwaki, MD, PhD

Blood (2004) 104 (11): 3267.

https://doi.org/10.1182/blood.V104.11.3267.3267

Published: 2004

Journal Articles

Serum-Soluble Tumor Necrosis Factor Receptor 2 (sTNF-R2) Level Determines Clinical Outcome in Patients with Aggressive Non-Hodgkin’s Lymphoma.

Hisashi Tsurumi, MD, PhD, Naoe Goto, MD, Masao Takemura, PhD, Takeshi Hara, MD, PhD, Michio Sawada, MD, PhD, Toshiki Yamada, MD, PhD, Senji Kasahara, MD, PhD, Nobuhiro Kanemura, MD, Takeshi Takahashi, MD, PhD, Masami Oyama, MD, PhD, Eiichi Tomita, MD, PhD, Tsuyoshi Takami, MD, PhD, Hisataka Moriwaki, MD, PhD

Blood (2004) 104 (11): 3271.

https://doi.org/10.1182/blood.V104.11.3271.3271

Published: 2004

Journal Articles

Unrelated cord blood transplantation for adult patients with de novo acute myeloid leukemia

Jun Ooi, Tohru Iseki, Satoshi Takahashi, Akira Tomonari, Kashiya Takasugi, Yoko Shimohakamada, Toshiki Yamada, Koji Ishii, Nobuhiro Ohno, Fumitaka Nagamura, Kaoru Uchimaru, Arinobu Tojo, Shigetaka Asano

Blood (2004) 103 (2): 489–491.

https://doi.org/10.1182/blood-2003-07-2420

Published: 2004

NARROW

Real-World Experience of Pola-R-CHP Therapy in Diffuse Large B-Cell Lymphoma Aged 80 or Older

A Comparison of THP- Cop and CHOP for Peripheral T-Cell Lymphoma, Not Otherwise Specified

A Randomized Phase II/III Study of R-THP-Cop Vs R-CHOP for Patients Younger Than 70 Years with DLBCL

High Response Rate and Acceptable Toxicity of R-P-Imvp-16/CBDCA for Relapsed or Refractory Aggressive B-Cell Lymphoma

Serum Interleukin-18 Level Determines Clinical Outcome in Patients with Diffuse Large B-Cell Lymphoma in Rituximab Era.

A Phase II Study of the Combination Chemotherapy Consisted of Rituximab and THP-COP Regimen as First-Line Treatment for Patients with Diffuse Large B-Cell Lymphoma

Second Report of Clinical Significance of sFas for DLBCL Treated with CHOP and New Analysis of sFas for DLBCL Treated with R-CHOP.

Serum-Soluble Interleukin-2 Receptor (sIL-2R) Is an Extremely Strong Prognostic Factor for Patients with Peripheral T-Cell Lymphoma, Unspecified (PTCL-U).

The Combination of 9-cis Retinoic Acid Plus MEK Inhibitor Induces Apoptosis Via Dephosphorylation of Retinoid X Receptor α in HL-60R Cells.

Continuous Drip Infusion of Low Dose Cytrabine and Etoposide with Granulocyte Colony-Stimulating Factor for Elderly Acute Myeloid Leukemia Patients Hardly Tolerable Intensive Chemotherapy - Phase II Study.

Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies

Serum Interleukin-18 Levels Are Associated with Response to Treatment and Survival in Patients with Aggressive Non-Hodgkin’s Lymphoma.

Fas or Fas Ligand Expression Can Determine the Clinical Outcome of Germinal Center Type in Diffuse Large B Cell Lymphoma.

Serum-Soluble Tumor Necrosis Factor Receptor 2 (sTNF-R2) Level Determines Clinical Outcome in Patients with Aggressive Non-Hodgkin’s Lymphoma.

Unrelated cord blood transplantation for adult patients with de novo acute myeloid leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only